U.S., Oct. 29 -- ClinicalTrials.gov registry received information related to the study (NCT07901959) titled 'Safety and Tolerability of Metformin and Naproxen for Cancer Prevention in Fanconi Anemia' on Oct. 13.
Brief Summary: Finding effective ways to slow down or prevent the development of cancer in people with Fanconi anemia (FA) is a critical medical priority. Individuals with FA are at dramatically higher risk of developing aggressive cancers, particularly of the head and neck, and these cancers are difficult to treat with standard therapies such as surgery, chemotherapy or radiation. Because options for treatment are limited and outcomes are often poor, prevention strategies are urgently needed.
In this study, the investigators will...